结直肠癌血清与组织标志物概述:放射科医生入门
本文综述结直肠癌血清和组织肿瘤标志物在诊断、治疗及随访中的价值,组织标志物用于靶向化疗基因分型,液体活检正在评估中。标志物常与影像联合用于分期、疗效评估和复发判断,放射科医生需了解标志物与影像表现的关联,并关注新型影像生物标志物的研究进展。
要点
- 肿瘤标志物与影像联合用于分期、治疗决策、疗效评估和复发监测。
- 组织标志物基于肿瘤细胞基因分型指导靶向化疗规划。
- 新型影像技术正被评估为预测基因型、特征和疗效的无创标志物。
核心结论
- 血清和组织肿瘤标志物在结直肠癌诊断、治疗和随访中提供关键信息,放射科医生应了解其与影像表现的关联。
研究设计与样本
- 综述类文章,总结结直肠癌血清与组织肿瘤标志物的临床应用及新型影像技术的研究进展。
临床应用与阅片要点
- 阅片和报告时应结合肿瘤标志物信息,辅助初始分期、治疗决策、疗效评估和复发或转移的判断。
- 关注基于肿瘤基因分型的组织标志物,以理解靶向化疗规划的背景。
- 了解液体活检等血浆标志物技术的评估进展,及其与影像联合应用的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Serum and tissue tumor markers provide crucial information in the diagnosis, treatment, and follow-up of colorectal cancers. Tissue tumor markers are increasingly used for determination of targeted chemotherapy planning based on genotyping of tumor cells. Recently, plasma-based technique of liquid biopsy is being evaluated for providing tumor biomarkers in the management of colorectal cancer. Tumor markers are commonly used in conjunction with imaging during initial staging, treatment determination, response assessment, and determination of recurrence or metastatic disease. Knowledge of tumor markers and their association with radiological findings is thus crucial for radiologists. Additionally, various novel imaging techniques are being evaluated as potential noninvasive imaging biomarkers to predict tumor genotypes, features, and tumor response. We review and discuss the potential role of these newer imaging techniques.
引用
- Bonde A, Smith DA, Kikano E, et al. Overview of serum and tissue markers in colorectal cancer: a primer for radiologists. Abdom Radiol (NY). 2021. PMID: 34415413. doi:10.1007/s00261-021-03243-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。